Cipla Limited — PPTs, 23-07-2026: Investor Presentation

Cipla reported its highest-ever Q1 revenue of INR 7,119 Cr. This growth was fueled by robust performance in 'One India', which grew 12% year-on-year, and 'One Africa', where the private business outpaced market growth. North America also contributed with a 5% year-on-year increase.

Profit for the period (PAT) was INR 789 Cr, with an 11.1% margin. The company's strategy focuses on expanding its portfolio, with new product launches like Yurpeak and Duolin Syncrobreathe driving double-digit growth in key chronic therapies in India. Cipla also launched its first AB-rated gVentolin in the US market during the quarter. Significant market share gains were seen in India Rx, growing 183 basis points faster than the overall market. The company is actively progressing on ESG goals, aiming for 80% renewable electricity and water neutrality for India manufacturing.